JORVEZA: A Non-halogenated Glucocorticosteroid Which Acts Primarily Anti-inflammatory Via Binding to the Glucocorticoid Receptor - Drug Insight and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com
15 Dec 2023
DUBLIN--(BUSINESS WIRE)--The "JORVEZA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
'JORVEZA Drug Insight and Market Forecast - 2032'
This report provides comprehensive insights about JORVEZA for Eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the JORVEZA for EoE in the 5MM, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the JORVEZA for EoE.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JORVEZA market forecast analysis for EoE in the 5MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.
Drug Summary
Budesonide is a non-halogenated glucocorticosteroid, which acts primarily anti-inflammatory via binding to the glucocorticoid receptor. In treating EoE with JORVEZA, budesonide inhibits the antigen-stimulated secretion of many pro-inflammatory signal molecules such as thymic stromal lymphopoietin, IL-13, and eotaxin-3 in the esophageal epithelium, which results in a significant reduction of the esophageal eosinophilic inflammatory infiltrate.
The efficacy and safety of JORVEZA were evaluated for the induction of clinicopathological remission of EoE in adults in pivotal clinical studies EOS-1 and EOS-2. Additionally, the EMA granted ODD to budesonide for the treatment of EoE. The recommended daily dose is 2 mg budesonide as one 1 mg tablet in the morning and one in the evening. The usual duration of treatment is 6 weeks.
JORVEZA Analytical Perspective
In-depth JORVEZA Market Assessment
This report provides a detailed market assessment of JORVEZA for eosinophilic esophagitis (EoE) in the seven major markets, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.
JORVEZA Clinical Assessment
Key Questions
What is the product type, route of administration and mechanism of action of JORVEZA?
What is the clinical trial status of the study related to JORVEZA in eosinophilic esophagitis (EoE) and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JORVEZA development?
What are the forecasted sales of JORVEZA in the seven major countries, including Europe (Germany, France, Italy, Spain) and the United Kingdom?
Which are the late-stage emerging therapies under development for the treatment of EoE?
Key Topics Covered:
1. Report Introduction
2. JORVEZA Overview in EoE
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Regulatory Milestone
2.4. Other Developmental Activities
2.5. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. JORVEZA Market Assessment
5.1. Market Outlook of JORVEZA in EoE
5.2. 5MM Analysis
5.2.1. Market Size of JORVEZA in the 5MM for EoE
5.3. Country-wise Market Analysis
6. SWOT Analysis
7. Analysts' Views
For more information about this report visit https://www.researchandmarkets.com/r/437ylh
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.